Loading
Life sciences · Journal article
Frontiers in Cardiovascular Medicine · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Anthracycline-related cardiac dysfunction remains a major concern in multiple myeloma, yet conventional left ventricular ejection fraction (LVEF) surveillance may miss early injury. We evaluated whether pre-anthracycline baseline measurements of high-sensitivity cardiac troponin I (hs-cTnI), global longitudinal strain (GLS), and coronary artery calcium (CAC), obtained before anthracycline initiation, improve risk stratification for cancer therapy-related cardiac dysfunction (CTRCD). Methods In this retrospective study of 312 myeloma patients receiving anthracycline-based therapy, CTRCD was defined as LVEF decline >10% to <53% or relative GLS decline >15%. Predictive performance was assessed using competing-risk models and time-dependent ROC analysis. A simplified risk score (MY-CARD) was derived and temporally validated in a separate cohort. Results CTRCD occurred in 91 patients (29.2%). hs-cTnI elevation and GLS worsening preceded LVEF decline, with median intervals of 8.4 and 12.6 weeks. The full model (hs-cTnI + GLS + CAC) achieved an AUC of 0.91, outperforming hs-cTnI + LVEF (0.83) and LVEF alone (0.66). The MY-CARD score stratified 12-month CTRCD risk into low (6.2%), intermediate (28.7%), and high (71.4%) categories. Patients with both hs-cTnI elevation and GLS worsening had the highest subsequent CTRCD risk (adjusted HR 5.42–7.86). Conclusions Integrating baseline hs-cTnI, GLS, and CAC improved CTRCD risk stratification in myeloma patients. The MY-CARD score provides a practical framework for baseline and on-treatment risk assessment, supporting closer surveillance in high-risk patients. External validation and prospective studies are warranted.